Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Aviditi Advisors

Tracked across 2 events · 27 articles · First seen Aug 05, 2026 · Last active Sep 08, 2026

Sentiment
-5
Attention
6
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 -60
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Acquired by Novartis for $12 billion; its lead drug del-desiran failed, undermining the value of the acquisition.
Sep 08, 2026 · 21 articles
1 50
Business
Impact: Aviditi Advisors, as part of Piper Sandler Companies's advisory group, played a key role in placing the fund, benefiting from the successful close.
Aug 05, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Aviditi Advisors live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.